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Abstract
Background:Neuroinflammation has recently been proposed to be a major component of neurodegenerative diseases. The aim
of this study was to determine how the interaction between microglia and astroglia, which are the primary immune cell populations in
the brain, and pathological prion protein (PrPsc) could influence the development and propagation of this neurodegenerative disease.
Because a relevant role for glial response in prion disease has been clearly demonstrated in our previous studies using the natural
animal model, a similar approach has been taken here using the natural human model.
Methods: A morphological approach has been developed to analyze cerebellar samples from patients with Creutzfeldt-Jakob
disease (CJD) in comparison with healthy control cases. Histopathological lesions were assessed, and PrPsc, glial fibrillary acidic
protein (GFAP) and reactive microglia were immunolabelled by specific antibodies. Furthermore, co-location studies using confocal
microscopy were performed to determine the possible relationships between both types of glial cells in all samples.
Results: The results presented in this study support the involvement of both types of glial cells in CJD. Evidence of increased
astrocyte and microglia reactivity can be observed in all CJD cases, and a close relationship between the types of glia is
demonstrated by co-location studies.
Conclusion:Proteinopathies such as Alzheimer, Parkinson, and Huntington diseases, where aberrant proteins spread throughout
the brain during disease progression, may share a molecular basis and mechanisms of propagation. Therefore, studies elucidating
the interaction between gliosis and prion propagation may be relevant to these other neurodegenerative diseases and may provide
new targets for therapeutic intervention.
Abbreviations: CD68 = cluster of differentiation 68, CJD = Creutzfeldt–Jakob disease, CNS = central nervous system, GFAP =
glial fibrillary acidic protein, H2O2 = hydrogen peroxide, HE = hematoxylin-eosin staining, IHC = immunohistochemistry, MHC II =
major histocompatibility complex type II, PBS = phosphate-buffered saline, PRNP = prion protein gene, PrPsc = pathological prion
protein, RT = room temperature.
Keywords: astrocytes, cerebellum, immunohistochemistry, microglia, neuroinflammation, prion diseases1. Introduction
According to the current neuroinflammation hypothesis associated
with neurodegenerative diseases, the key element underlying the
pathogenesis of these disorders involves microglial cells. Their
activation is widely assumed to be a marker of pathogenic
neuroinflammation in these disorders. Although microglia are
generally considered the resident immune cells in the brain, the
impact of astrocytes on inflammation cannot be understated.[1]
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1microglia and initiate a series of inflammatory responses, directly
affecting neuronal functions. The term gliosis has been applied so
broadly that it can either cease to impart useful information or be
entirely misleading,[2] starting with inconsistent premises on some
occasions. The lack of understanding of the actual neurodegenera-
tive processes likely slows the progress of research in this field. In
addition,while the pathogenesis of these neurodegenerative diseases
remainsunknown,no truly effective treatments canbe identified that
might prevent the onset or delay the progression of these diseases.
Current evidence supports the idea that many neurodegenera-
tive diseases (those belonging to a prion-like disorder group)[3]
involve aberrant protein accumulation, similar to that observed
in prion diseases, turning studies elucidating the mechanisms of
prion propagation into useful tools for the study of other
neurodegenerative diseases.
Although gliosis is always cited as one of the hallmarks of prion
diseases, little research has been performed that focused on the
involvement of glial cells in prion diseases to elucidate their roles.
According to our initial studies regarding the pathogenic progress
of Scrapie, as a prototype of prion diseases, astroglia is involved
in Scrapie evolution.[4] This glial population has been suggested
to sustain active prion propagation[5] and to exist in a close
relationship with the vacuoles that form the primary neurode-
generative lesion found in this group of diseases.[6] Based on these
encouraging results, the proposal here consists of extending the
study on glial involvement from animal to human samples.
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following reasons. First, based on anatomical and physiological
characterization, the cerebellum is particularly vulnerable to
insults, and abnormalities in the cerebellum are usually easy to
recognize.[7] Second, the cerebellum is one of the areas most
affected by pathological prion protein (PrPsc) accumulation,
regardless of the subtype associated with the affected individuals,
and ataxia is one of the most frequent symptoms. Third, previous
studies that focused on microglial cells in prion diseases found no
differences between the cerebellum and other brain areas;[8]
consequently, the conclusions drawn from studying the cerebel-
lum can be extrapolated to the whole encephalon. In addition,
this encephalic area has been proposed to serve as a pseudo-
reference region to detect neuroinflammation.[9]
The specific goal of this study was to assess whether the
expression of astroglia and reactive microglia markers in
cerebellar sections from patients with Creutzfeldt–Jakob disease
(CJD) differed from those of control patients. This study also
aimed to establish a possible relationship between the differential
expression of glial and PrPsc deposition and/or neuropathologi-
cal alterations in human cerebellar samples.2. Materials and methods
2.1. Samples
All samples were provided by the human tissue bank from
Hospital de Alcorcón (HUFA Biobank, Madrid, Spain), follow-
ing the guidelines provided by Spanish legislation.
Samples corresponded to a total of 25 CJD patients (age range:
48–82 years; sex: male and female; genotypes at codon 129 of
PRNP: homozygous and heterozygous), including 22 sporadic
and 3 familial cases (PRNP E200K mutation). Five additional
samples were used as healthy controls (age range: 36–82 years).
Fixed sections (4% paraformaldehyde), corresponding to
cerebellar sagittal samples at the vermal level, were obtained
and included the granular, Purkinje cell, andmolecular layers and
white matter for all samples.
The studies performed on samples were approved by the
Ethical Committee for Clinical Research from Government of
Aragón (CEICA; REFERENCE NUMBER: PI15/0036, Acta No
05/2015).2.2. Methodology
Five-millimeter slices from each individual were paraffin-
embedded, from which 5mm sections were taken and histologi-Figure 1. The scoring system used after HE staining to assess spongiosis by light m
abundant (++++). Scale bars: 50mm. HE = hematoxylin-eosin staining.
2cally (hematoxylin-eosin staining [HE]) or histochemically
processed, following formic acid treatment for prion inactivation.
The remaining portions were processed for confocal microscope
studies.
To detect PrPsc, GFAP, and reactive microglia, immunohisto-
chemical (IHC) protocols were followed, using specific antibodies
in DAKO antibody diluent (Faramount DAKO, Glostrup,
Denmark), on sections transferred to Vectabond-treated slides
and incubated at 56°C overnight. DAB PLUS was used as a
chromogen, and hematoxylin counterstaining and mounting in
mounting medium (Faramount DAKO, Glostrup, Denmark)
were performed on all sections, regardless of the immunohisto-
chemical protocol applied.
After HE staining, all samples were assessed by light
microscopy to determine histopathological lesions. All of the
layers from each sample were examined for spongiosis and
subjectively scored according to the number of vacuoles, that is,
(), absent to (++++), very abundant (Fig. 1). After IHC
processing, all marker immunostaining was scored from negative
() to maximum (++++), by evaluating the density and the extent
of the labelled deposits in each layer from each cerebellum, using
light microscopy (Fig. 2). The immunostaining morphologies of
each marker were also assessed: linear, granular, spot, coalescent
or plaques, for PrPsc; stellate, perineuronal or radial, for GFAP;
ramified or amoeboid, for reactive microglia (Fig. 3).
Studies using confocal microscopy were performed to assess
the possible relationship between astrocytes and reactive micro-
glia in all cases.
2.2.1. Immunohistochemical protocol for PrPsc detection by
optical microscopy. It was necessary to include an epitope
unmasking protocol, consisting of 96% formic acid immersion (5
minutes), digestion with proteinase K (5minutes, room tempera-
ture [RT]; Life Technologies) and autoclaving in distilled water
(10minutes). After incubation with a primary antibody that
recognizes prion protein (12F10 at 1/1700 dilution; SPI Bio,
Darmstadt, Germany) for 1hour at RT, sections were incubated
for 30minutes at RT with EnVision mouse polymer (DAKO,
Glostrup, Denmark), which was used as a visualization system.
2.2.2. Immunohistochemical protocol for GFAP detection by
optical microscopy. After endogenous peroxidase blocking
(H2O2 33%) for 5minutes, sections were incubated with a
primary antibody that specifically recognizes glial fibrillary acidic
protein (GFAP 1/500, 30minutes, RT; DAKO), as an astrocytic
protein marker. Incubation with the labelled EnVision rabbit
polymer (30minutes, RT; DAKO) was performed.icroscopy, according to the number of vacuoles: from (A) very scarce to (D) very
Figure 2. The scoring system used after IHC protocols to evaluate the density and the extent of the labelled deposits (brown; hematoxylin counterstaining, blue) by
light microscopy: from minimum to maximum, for PrPsc (A–D); GFAP (E–H); and reactive microglia (I–L). Scale bars: 100mm. GFAP = glial fibrillary acidic protein,
IHC = immunohistochemistry, PrPsc = pathological prion protein.
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detection by optical microscopy. Endogenous peroxidase
blocking (H2O2 33%, 5minutes), followed by incubation for
30minutes at RT with major histocompatibility complex type II
(MHC II) (1/200; DAKO, Denmark) and CD68(1/500; DAKO)
primary antibodies, was used to immunolabel reactive microglial
cells. EnVisionTMpolymer (mouse, 30minutes, RT; DAKO) was
used as a visualization system.
2.2.4. Immunohistochemical protocol for confocal micros-
copy studies. The protocol applied for co-location studies was
based on a previously described version.[5] Briefly, 50mm sections
from fixed samples were collected in PBS (floating). Endogenous
peroxidase blocking (H2O2 33%, 30minutes) was followed by
incubation with Triton X 100 (0.1% in PBS for 3hours, RT).
Subsequently, incubation with the same specific antibodies, at the
same concentrations as described above, was used to individually
label reactive microglia and astrocytes (i.e., GFAP, MHC II, and
CD68, in PBS-Triton 0.1%). The secondary conjugated anti-
bodies Alexa 488(1/200; Invitrogen, Eugene, OR) and Alexa 594
(1/200, Invitrogen) were added in PBS for 1hour in the dark prior
to assessment by confocal microscopy (Zeiss LSM 510).
The fluorescence emissions, with excitation from 488 and 594
nm lasers, were detected with a 2-channel multitrack configura-
tion, using bandpass 505 to 530nm and long-pass 615-nm filters,
respectively. Z-stacks of digital images were captured using Zen32008 software (Carl Zeiss Microimaging, Jena, Germany) and
collapsed into 1 resulting picture using the maximum intensity
projection provided by the software.3. Results
All samples corresponding to CJD patients showed spongiosis.
Spongiosis intensity varied among samples, but it was similar in
all layers within each cerebellum, except for 2 occasions. In 1
case, the highest intensity was found in the Purkinje cell layer and
the lowest in the granular layer, and the opposite scores were
found in the remaining case. Control samples did not show
spongiosis in any cases (Table 1).
One control and 3 CJD cases presented with the total
degeneration of the granular layer.
In CJD cerebella, an evident decrease in nuclei count, as well as
neurite thickening, was frequently observed in Purkinje cells.
Furthermore, protein aggregates were clearly evident in the
molecular and Purkinje cell layers by optical microscopic
examination. Kuru plaques were exclusively found in 1 CJD
patient (Fig. 4).
A wide range of PrPsc deposit profiles was found in the
cerebella from CJD patients, although granular and coalescent
patterns were the most frequently observed patterns in the
molecular and granular layers, respectively. The lowest intensity
of protein deposit immunolabeling was detected in the Purkinje
Figure 3. Immunohistochemical patterns observed when each marker (brown; hematoxylin counterstaining, blue) was assessed. For PrPsc: (A) linear, (B) plaques,
(C) spots, (D) coalescent, and (E) granular. Scale bars: 20mm in (A); 50mm in (B–E). For GFAP: (F) stellate, (G) perineuronal, and (H) radial. Scale bars: 50mm in F and
H; 20mm in G. For reactive microglia: (I) ramified and (J) amoeboid. Scale bars: 20mm. GFAP = glial fibrillary acidic protein, PrPsc = pathological prion protein.
Monzón et al. Medicine (2018) 97:15 Medicinecell layer and in white matter. Specific immunostaining against
PrPsc was not always present in protein aggregates. No PrPsc
deposits were found in any control samples (Fig. 5).
Samples from CJD patients showed an increase in GFAP
immunostaining compared with healthy controls, which was
especially evident in white matter. Specific astroglial immuno-
staining always appeared to be associated with protein
aggregates, regardless of the presence of PrPsc deposition.
Our previous findings regarding astroglial immunostaining in
CJD samples[10] were also confirmed here. An increase in the level
of immunolabeling surrounding Purkinje cells and next to4meninges was observed, and intense radial gliosis or large
numbers of varicose fibers parallel to the pial surface were
observed in the molecular layer from cerebella with higher or
lower GFAP intensity, respectively (Fig. 6).
Immunolabelling corresponding to reactive microglia was
found scattered over all examined areas in control cerebella. It
primarily presented a ramified morphology, except for in the
cerebellum that had a degenerated granular layer, where an
amoeboid morphology was found. CJD samples demonstrated
clear microglial reactivity, as the intensity of immunolabelling
was higher in all affected cases compared with controls. Although
Table 1
Scores provided by light microscopy examination corresponding to each layer from each cerebellar sample for spongiosis after HE
staining (according to the number of vacuoles: , absence / ++++, very high number in gray matter) or immunolabeling for each specific
marker used after IHC processing (by evaluating the density and the extension of the labelling deposits: , negative / ++++, maximum).
Sample Layers Spongiosis PrPsc GFAP Reactive microglia
CJD 1 Molecular +++ + + +
Purkinje cell – + + +
Granular ++++ + + +
White matter – ++ ++
CJD 2 Molecular ++ + + +
Purkinje cell ++ + ++ +
Granular +++ ++ + +
White matter – +++ +
CJD 3 Molecular + ++ + +
Purkinje cell ++ +++ ++ +
Granular ++ ++++ + +
White matter ++ +++ +++
CJD 4 Molecular ++++ ++ ++++ +
Purkinje cell ++++ + +++ +
Granular +++ +++ +++ +
White matter – ++++ +++
CJD 5 Molecular + + + ++
Purkinje cell +++ + ++ +
Granular – ++ + +
White matter – +++ +
CJD 6 Molecular +++ + + +++
Purkinje cell ++ + ++ +
Granular ++ + + +
White matter – ++ ++
CJD 7 Molecular +++ ++ +++ +++
Purkinje cell ++ + +++ +
Granular ++++ +++ ++ +++
White matter – +++ +
CJD 8 Molecular + + + +
Purkinje cell ++++ ++ ++ +
Granular ++++ +++ + ++
White matter + +++ +++
CJD 9 Molecular +++ ++ + +++
Purkinje cell ++ + ++ +++
Granular ++ +++ + +++
White matter + +++ +
CJD 10 Molecular + + + +
Purkinje cell ++++ ++++ ++ +
Granular ++ +++ + +
White matter ++++ +++ +++
CJD 11 Molecular ++++ ++ +++ +++
Purkinje cell ++ + +++ +
Granular ++++ +++ +++ +++
White matter – ++ ++
CJD 12 Molecular ++++ ++ ++ ++
Purkinje cell ++++ + ++ +
Granular ++++ +++ ++ +
White matter – ++++ +
CJD 13 Molecular +++ +++ +++ ++++
Purkinje cell ++ + +++ +++
Granular +++ ++++ ++ +++
White matter + +++ +
CJD 14 Molecular +++ ++ ++ ++
Purkinje cell ++++ + +++ +
Granular ++++ +++ ++ +
White matter – +++ +
CJD 15 Molecular +++ ++ + ++
Purkinje cell ++++ + + +
Granular ++ + + +
White matter – +++ ++
CJD 16 Molecular ++++ ++ + ++
(continued )
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Table 1
(continued).
Sample Layers Spongiosis PrPsc GFAP Reactive microglia
Purkinje cell ++++ + + +
Granular ++++ ++ + +
White matter – ++ +
CJD 17 Molecular +++ ++ +++ ++++
Purkinje cell ++ + +++ +
Granular +++ ++ ++ ++++
White matter – +++ ++++
CJD 18 Molecular ++++ ++ +++ +++
Purkinje cell ++ + +++ +++
Granular +++ +++ ++ +++
White matter – +++ +
CJD 19 Molecular +++ + + +++
Purkinje cell ++++ + + +
Granular ++++ ++ + +
White matter – ++ +
CJD 20 Molecular +++ + + +
Purkinje cell ++ + + +
Granular +++ ++ + +
White matter – ++ +
CJD 21 Molecular +++ +++ +++ ++
Purkinje cell ++++ + +++ +
Granular ++++ ++++ ++ +++
White matter + +++ +++
CJD 22 Molecular ++++ + – +++
Purkinje cell ++++ + + +
Granular ++++ ++ – ++
White matter – ++ ++
CJD 23 Molecular ++++ + ++ ++
Purkinje cell ++++ + ++ +
Granular ++ ++ ++ ++
White matter – +++ ++
CJD 24 Molecular +++ ++ + +++
Purkinje cell ++++ + ++ +
Granular ++ +++ + +++
White matter – +++ +
CJD 25 Molecular + + + +
Purkinje cell ++++ +++ ++ +
Granular + +++ + +
White matter + +++ ++
Control 1 Molecular – – ++ +
Purkinje cell – – ++ +
Granular – – + +
White matter – +++ ++
Control 2 Molecular – – + +
Purkinje cell – – + +
Granular – – + +
White matter – +++ +
Control 3 Molecular – – + +
Purkinje cell – – + +
Granular – – + +
White matter – +++ +
Control 4 Molecular – – + +
Purkinje cell – – ++ +
Granular – – + +
White matter – +++ +
Control 5 Molecular – – + +
Purkinje cell – – + +
Granular – – ++ +
White matter – – +++ ++
CJD = Creutzfeldt–Jakob disease, HE = hematoxylin-eosin staining, IHC = immunohistochemistry.
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igure 5. Primary observations provided by light microscopic examination after the application of the IHC protocol for PrPsc detection (brown; hematoxylin
ounterstaining, blue). A, Purkinje cell layer and white matter from CJD cerebella always corresponded to the lowest intensity of protein deposit immunolabeling. B,
rotein aggregates were not always associated with PrPsc immunostaining. C, PrPsc deposits were never observed in healthy controls. Scale bars: 50mm in (A);
0mm in (B); 200mm in (C). CJD = Creutzfeldt–Jakob disease, IHC = immunohistochemistry, PrPsc = pathological prion protein, RT = room temperature.
Figure 4. Primary histopathological findings observed by light microscopic examination after HE staining. A, Control samples did not show spongiosis in any cases.
B, A total degeneration of the granular layer was found in one control, as illustrated, and in 3 CJD cases. C, An evident decrease in the nuclei count and neurite
thickening were frequently observed in Purkinje cells from CJD compared with (D) control cerebella. E, Protein aggregates were clearly evident in the Purkinje cell
layer (on the left) and in the molecular layer (on the right) in several prion-affected cerebella. F, Kuru plaques were only found in the cerebellum from 1 CJD patient.
Scale bars: 200mm in (A) and (B); 50mm in (C) and (D); 20mm in (E) and (F). CJD = Creutzfeldt–Jakob disease, HE = hematoxylin-eosin staining.
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Figure 6. Primary observations provided by light microscopic examination after the application of the IHC protocol for GFAP detection (brown; hematoxylin
counterstaining, blue). In comparison with those from healthy controls (A) and (B), the increase in GFAP immunostaining in CJD cerebella was specially evident
around Purkinje cells (C) and (D) white matter. E, Protein aggregates always appeared associated with astroglial immunostaining. F, GFAP immunolabeling was
evident next to the meninges in some CJD samples. G, An intense radial gliosis in the molecular layers was primarily found in CJD cerebella with higher GFAP
intensity. H, Meanwhile, a large number of varicose fibers parallel to the pial surface were observed in CJD cerebella with lower GFAP intensity. Scale bars: 50mm in
(A), (C), (G), and (H); 200mm in (B) and (D); 20mm in (E); 100mm in (F). CJD = Creutzfeldt–Jakob disease, GFAP = glial fibrillary acidic protein, IHC =
immunohistochemistry.
Monzón et al. Medicine (2018) 97:15 Medicinethe distribution of the microglial population (primarily located in
white matter or in the molecular and/or granular layers) varied
among CJD-affected cases, Purkinje cells were not found to be
in a close relationship with this glial population. Moreover, a
ramified morphology was primarily observed in the Purkinje cell
layer. Immunostaining with amoeboid shapes was more
frequently found in white matter (Fig. 7).
When confocal microscopy was used to determine a possible
interaction between the two glial populations studied here,
samples corresponding to CJD patients demonstrated interac-8tions to a greater extent than control samples. Astrocytes were
observed surrounding microglia in some occasions (Fig. 8).
4. Discussion
The function of the central nervous system has been long
explained by a neurocentric vision, attributing all the primary
information processing activities to neuronal cells. In recent
years, several studies have challenged this concept, revealing that
non-neuronal cell components, particularly glial cells, perform a
Figure 7. Primary observations provided by light microscopic examination after application of the IHC protocol for reactive microglia detection (brown; hematoxylin
counterstaining, blue). A, An amoeboid morphology was found in a degenerated granular layer. B, Purkinje cells were not found to be in close association with
reactive microglia. Ramifiedmorphology was primarily observed in this cell layer. C, Meanwhile, amoeboid shapes weremore frequently found in white matter. Scale
bars: 50mm in (A); 20mm in (B) and (C). IHC = immunohistochemistry.
Monzón et al. Medicine (2018) 97:15 www.md-journal.comdynamic range of functions that are essential for the physiology of
the brain.[11,12] Thus, there is growing consensus that a more
integrated level of neuroglial interactions needs to be considered
to have a comprehensive overview of brain functions and
dysfunctions. The observations presented here support the
relevance of this interaction in the progression of neuro-
degeneration associated with prion diseases.
Glial activation had been assumed to be merely a response to
pathophysiological events. However, recent data from preclinical
and clinical studies have established that immune system-
mediated actions contribute to and drive neurodegenerative
disease pathogenesis. Neuroinflammation has become a current
hypothesis for the basis of neurodegeneration.[13]
The fact that microglia play multiple roles in prion diseases is
well established. This glial population is assumed to play a major
role in the pathological changes in these diseases.[14] The present
study assessed a number of CJD cases for reactive microglia in the
brains of affected patients in comparison with controls. An
increase in reactive microglia has only been described in 2 cases in
previous studies.[15,16] Based on animal models it has been
suggested that microglial activation precedes neuronal loss.[17,18]
In addition, an inflammatory response mediated by microglia,
astrocytes, and cytokines in these diseases has been proposed to
be an early event in the pathogenesis of disease and appears to
remain activated for the duration of the disease.[19] These
excessive inflammatory mediators could contribute to neuronal
damage. Therefore, the results presented here support the ideaFigure 8. Images obtained by confocal microscopy for the detection of both types o
microglia (red) and astroglia (green) in cerebella from (A) CJD patients than in (B) co
Creutzfeldt–Jakob disease.
9that the inhibition of microglial over-activation could be a
therapeutic strategy for alleviating microglia-mediated neuro-
inflammation.
Although the microglial response is thought to be more
pronounced in the immature brain[20,21] and in earlier stages of
neurodegenerative disease,[22] the findings described here
demonstrate that the capacity to process and/or maintain this
response against specific stimuli remains, despite aging and
disease progression.
It is known that activated microglia up-regulate many surface
receptors, such as theMHC, or complement receptors, secreting a
variety of soluble biologically active factors. The morphofunc-
tional spectrum of microglia is highly regulated and is reflected by
various intermediate states of activation. The malleability of
phenotype appears to be the result of the very graded manner of
glial cell response to changes in the environment.[23] There is an
accepted distinction between phagocytosis by ramified and
amoeboid microglia during basal conditions and neurodegener-
ation, respectively.[24,25] However, the high phagocytic potential
of unchallenged microglia may be even further enhanced during
neurodegeneration,[26] which could explain the observations of
both phenotypes in the present study, as the antibodies that have
been used here to recognize immunological activity.
The loss of microglial integrity may also contribute to tissue
pathology.[27] It is known that transformed microglial cells are
indicative of a loss of tissue homeostasis. Phenotypically
transformed microglia should consequently raise suspicions thatf glial cells assessed in this study showed amore extensive interaction between
ntrol patients (objectives: 10, NA-03, capturing ROI and CROP scan). CJD =
Monzón et al. Medicine (2018) 97:15 Medicineintrinsic tasks are not being performed efficiently. The amoeboid
pattern primarily observed in the white matter from CJD
samples, in this study, could be explained by a loss of microglial
functions and the consequent enhancement of disease conditions.
A low accumulation of PrPsc aggregates was found in this layer.
Microglial activation is followed by astrocyte activation.
Activated microglia can initiate and maintain astrogliosis. This
suggests that the suppression of microglial over-activity might
effectively attenuate reactive astrogliosis.[28] Prion disease
pathogenesis entails altered astrocyte function, which may be
considered an integral part of the neuroinflammatory response.
The presence of activated astrocytes around PrPsc deposits is well
documented in prion diseases.[29] In agreement with the
observations presented here, glial disorders should not be
considered a late reaction to neuronal injury but rather as an
intrinsic component of the pathological process. In fact,
astrocytes not only form a glial scar in central nervous system
diseases,[30] but their activation may occur early in the course of
neurodegenerative pathogenesis. Because hypertrophy shown by
this glial population eventually results in deficient glutamatergic
transmission, they could possibly contribute to cognitive
impairment.[31]
With this study, a model of neuronal death in prion disease has
emerged, indicating that both microglia and astrocytes can either
induce or exacerbate neuronal death induced by the abnormal
prion protein isoform. Despite some claims that the neurotoxic
effect of PrPsc does not require the effects of glia, gliosis and
astrogliosis, appear to be clearly involved in the deleterious
mechanism of the toxic prion protein. Perhaps a combination of
astroglial and microglial effects could explain the neuroinflam-
mation hypothesis by mediating or exacerbating the toxic effects
of protein accumulation in the brain. It had been demonstrated
that astrocytes can also act on microglia, creating a paracrine,
and autocrine feedback loop, whereby microglia and astroglial
derived factors regulate each other.[32,33] As a consequence,
gliosis would mediate neuronal death. Microglial impairment
might paradoxically be sustained by inflammatory cytokines.
This suggests that neuropathology could be accelerated through a
negative feedback loop. Ultimately, prolonged microglia im-
pairment would also be accompanied by a loss of trophic
functions and the elimination of protective properties. In vivo
Alzheimer disease experiments have suggested that the coexis-
tence of microglia and astroglia diminishes the ability of
microglia to digest and degrade plaques.[34] Therefore, activated
astrocytes may exert a regulatory effect (negative feedback) on
the phagocytic activity of microglia. The close relationship,
demonstrated here by confocal studies, between astrocytes and
microglia, combined with the increase in both activated glial
populations, would support this cooperative action for neuronal
damage.
In addition to microglia and astrocytes, other CNS resident
cells, such as endothelial cells, can contribute to neuroinflamma-
tion. Endothelial cells, a key element of the neurovascular unit,
have been demonstrated to contribute to the entry of misfolded
proteins into the brain in prion[5] and Alzheimer disease[35]
models. In this model, they have also been demonstrated to
influence inflammation, due to mechanisms influencing the efflux
of amyloid and neurotoxic species. Additionally, other proteins,
such as growth factors and adhesion molecules, may enable the
influx of immune cells into the brain.[36,37]
In 2004, Marín-Teva et al[38] demonstrated that microglia
promoted the death of Purkinje cells in the developing mouse
cerebellum. However, the limited detection of reactive microglia10and, by contrast, the increased presence of astroglia in the
Purkinje cell layer detected in this and previous[10] studies, would
suggest the relevant contribution or involvement of astroglia in
this task.
With regards to this neuronal cell type, Purkinje cells are the
dominant elements involved in the processing of cerebellar
information.[39] The cerebellum controls motor coordination,
balance, muscle tone, motor learning, and cognition. These
functions are partly mediated by neurons in the cerebellar cortex,
which receive excitatory input from the somatosensory system
and the cerebral cortex. These excitatory inputs are relayed by
glutamatergic mossy fibers, originating in the brain stem and
spinal cord. A single mossy fiber makes synaptic connections with
hundreds of granule cells, and thousands of these cells provide
excitatory input to Purkinje neurons. Inhibitory inputs are
provided by the molecular layer interneurons and perhaps by
Purkinje cells. In agreement with the histopathological findings
observed here, the number of Purkinje cells in older animals has
been shown to decrease throughout the cerebellar cortex,[40] and
Purkinje cells in older animals have been demonstrated to exhibit
torpedoes.[41] Moreover, defects have been described as second-
ary to Purkinje cell loss, including the significant loss of granule
cells.[42] It is difficult to determine whether Purkinje neuronal cell
loss occurs in a random or orderly fashion, because cerebellar cell
death is much more topographically complex that generally
appreciated.[7] All these findings about Purkinje cells were
similarly described in previous studies on Scrapie (prototype of
prion disease), where these neurons were concluded to play a
relevant role in neurodegeneration and were simultaneously the
most damaged and protected cell type in the studied area.[4,6]
In these previous morphological studies on Scrapie, a similar
intense radial gliosis was observed as was observed in some of the
CJD samples here, which corresponded to terminal stages of the
disease. Meanwhile, those showing an increasing number of
fibers parallel to the pial surface resembled nonterminal cases (a
lesser progression of neurodegeneration). A similar astroglial
pattern was also recently described in the cerebella of patients
with Alzheimer disease.[43] Some authors point to specific novel
glial cells as being good candidates for involvement in the
pathogenesis of this neurodegenerative disease,[44] based on their
proliferative properties and the capacity for neuron and astrocyte
regeneration.[45] Both features result in increased interest in this
cell type during neurodegeneration.
Understanding how glial response is triggered in association
with protein accumulation under the pathological conditions
characteristic of CJD may highlight novel targets for therapeutic
intervention, not only for prion disease but also for prion-like
disorders. In fact, several attempts to achieve therapeutic
interventions have been recently published. One of these studies
strongly supports the important contribution of microglia within
the prion disease process, identifying the nature of the response
through the gene expression analysis of isolated microglia.[46]
Our previous studies point to astroglial cells being involved in the
pathogenesis of not only CJD but also of Alzheimer disease.[10]
The consistent relationship between both microglia and astroglia
and protein aggregates, demonstrated in this morphological
study, constitutes an innovative contribution to understanding
prion diseases. This relationship has also been suggested to be
involved in various neurodegenerative disorders, such as
Alzheimer’s, Parkinson’s, or Huntington’s diseases, amyotrophic
lateral sclerosis, and multiple sclerosis.[47]
Finally, it would be relevant to emphasize the importance of
studying human brain material to provide reliable results. It has
[7] Sarna JR, Hawkes R. Patterned Purkinje cell death in the cerebellum.
Monzón et al. Medicine (2018) 97:15 www.md-journal.combecome a common practice in Neurobiology, and in research in
general, to extrapolate from experimental models to natural
disorders. However, there are large differences between animal
models and humans, and this is the likely reason why many
conclusions drawn from studies performed on animal models fail
to reflect actual mechanisms of disease. Unfortunately, these
studies have certain limitations, which prevent the formation of
broader conclusions. On many occasions, only partial data on
patients are available, and the clinical history, dominant
symptoms and even PrP genotype, are unknown.5. Conclusions
Proteinopathies, such as Alzheimer’s, Parkinson’s, or Hunting-
ton’s diseases, in which aberrant proteins spread throughout the
brain during disease progression, may share a molecular basis
and mechanisms of propagation. Therefore, studies elucidating
the interaction between gliosis and prion propagation are
relevant to these other neurodegenerative diseases, by providing
new targets for therapeutic intervention.
The observations presented here demonstrate the involvement
of astroglial and microglial cells in all of the CJD cases studied
and would support the current controversy about neuro-
inflammation as a cause of neurodegeneration.Acknowledgments
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